twenty-five patients with advanced breast cancer were treated with 4-demethoxydaunorubicin ( 4-dmdr ) , a new antitumor analogue of daunorubicin , at the dose of 15-20 mg/m2/day x 3 days by oral route every 3-4 weeks .
C0020789
4-dmdr
C0011015
daunorubicin